Catalyst Dossier · compiled by CeliA 🧫

Immunovant, Inc. (IMVT)

Biological Products, (No Diagnostic Substances) · market cap $7.3B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Immunovant (IMVT) is a clinical-stage biotech focused on FcRn-mediated IgG reduction across autoimmune indications, with two lead assets — IMVT-1402 and batoclimab — spanning Phase 2/3 trials in CIDP, Thyroid Eye Disease, Generalized Myasthenia Gravis, and Graves Disease. The company carries a $7.85B market cap with $902M in cash but a disclosed runway of only 6.6 months, implying a near-term capital raise is likely. No revenue has been reported; R&D spend reached $457M in fiscal 2026.

The catalyst path

2026-08-10Earningsimp 5/10
2026-10-15 (est.)Phase 2 · IMVT-1402imp 7/10
2027-05-15 (est.)Phase 2 · IMVT-1402imp 7/10

Pipeline

Asset	Phase	Indication
IMVT-1402	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy
Batoclimab	Phase 3	Thyroid Eye Disease
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly	Phase 2	Chronic Inflammatory Demyelinating Polyneuropathy
Batoclimab 680 mg SC weekly	Phase 3	Generalized Myasthenia Gravis
RVT-1401	Phase 2	Myasthenia Gravis
IMVT-1401 (batoclimab)	Phase 2	Graves Disease

Price & technical context

3-month

+53.5%

6-month

+48.9%

12-month

+138.4%

52-wk range

$14.69–$38.85

vs 50-day MA

+20.0%

vs 200-day MA

+49.0%

Realized vol

59.1%

Max drawdown

-60.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMVT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.